Synonyms: compound 50 [PMID: 34323489] | Example 34 [WO2019015655] | TQB-3804
Compound class:
Synthetic organic
Comment: TQB3804 is a fourth generation, ATP-competitive EGFR inhibitor [1]. It was designed to overcome EGFRC797S mutation-mediated resistance to third-generation irreversible inhibitors such as osimertinib.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Shaikh M, Shinde Y, Pawara R, Noolvi M, Surana S, Ahmad I, Patel H. (2022)
Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer. J Med Chem, 65 (2): 1008-1046. [PMID:34323489] |
2. Wu L, Liu X, Ding CZ, Chen S, Hu L, Zhao L, Pan W, Hu G, Li J, Zhao N et al.. (2019)
Aryl-phosphorus-oxygen compound as egfr kinase inhibitor. Patent number: WO2019015655A1. Assignee: Chia Tai Tianqing Pharmaceutical Group Co Ltd. Priority date: 19/07/2018. Publication date: 24/01/2019. |